Safety and Efficacy of Pazopanib As a Second-Line Treatment and Beyond for Soft Tissue Sarcomas: A Real-Life Tertiary-Center Experience in the MENA Region.

•Pazopanib is a tyrosine kinase inhibitor which is safe and effective in the management of soft tissue sarcomas after chemotherapy failure in developed countries. There is very little data available about this drug's use and effects in developing countries such as Lebanon.•In this retrospective analysis of 15 patients diagnosed with advanced soft tissue sarcoma and received pazopanib as second-line and beyond therapy after progression on at least one chemotherapy line, 86.7% of patients progressed, whereas 13.3% had stable disease thus response to pazopanib.•Median progression-free survival (PFS) was three months [1–19], and mean overall survival (OS) was 25.4 months [17.2–33.6]. Five patients required dose-reductions of pazopanib, with toxicities being poor tolerance with malaise and fatigue, and decreased appetite.•In our trial were small, our median PFS reached 3 months, which is quite comparable to that in SPIRE trial as well as the PALETTE trial where median PFS was 3 and 4.6 months respectively.•The small sample size in this study is probably indicative of the lack of use and lack of exposure of Lebanese physicians to this relatively safe therapeutic option. More focused studies within a larger population of patients using pazopanib alone or in combination, need to be done, in the middle eastern region.